1-甲基-5-噻吩-2-基-1H-吡唑-3-羰酰氯 | 876316-46-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-甲基-5-噻吩-2-基-1H-吡唑-3-羰酰氯
• 英文名称: 1-methyl-5-thien-2-yl-1H-pyrazole-3-carbonyl chloride
• 英文别名: 1-Methyl-5-(thiophen-2-yl)-1H-pyrazole-3-carbonyl chloride；1-methyl-5-thiophen-2-ylpyrazole-3-carbonyl chloride
• CAS: 876316-46-0
• 化学式: C₉H₇ClN₂OS
• mdl: MFCD08271953
• 分子量: 226.686
• InChiKey: GDRPADSBNGOLQL-UHFFFAOYSA-N

物化性质

• 熔点：
  48 °C
• 沸点：
  366.5±32.0 °C(Predicted)
• 密度：
  1.45±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  63.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  1-甲基-5-噻吩-2-基-1H-吡唑-3-羰酰氯 、 1,5-dimethyl-3,7-diazabicyclo[3.3.1]nonan-9-one 在 三乙胺 作用下， 以 水 、 苯 为溶剂， 以87%的产率得到(1,5-dimethyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3,7-diyl)bis((1-methyl-5-(thiophen-2-yl)-1H-pyrazol-3-yl)methanone)
  参考文献：
  名称：

  Bispidine 平台作为研究酰胺构型稳定性的工具

  摘要：

  在这项工作中，通过 NMR 光谱（包括 VT NMR 实验）研究了 17 种 3,7-二酰基双吡啶的溶液构象。酰基包括烷基、烯基、芳基、杂芳基和二茂铁部分。估计了顺式/反式异构体的存在及其比例，并阐述了解释实验事实的一些原因。特别是，无环 R(CO) 片段中的所有脂肪族和杂环单元导致 DMSO-d6 溶液中顺式形式的含量增加。相反，当 R = Ph、二茂铁基、(R)-桃金娘烯基时，在 DMSO-d6 和 CDCl3 中仅检测到反形式。对于衍生自天然萜烯桃金烯的手性化合物，除了酰胺 NC(O) 键周围的预期反转之外，还发现了新的动态过程。在这里，检测到无环 R 片段中围绕 CO-C=C 键的旋转，并估计其能量。对于该化合物，酰胺 NC(O) 反转的 ΔG 等于 15.0 ± 0.2 kcal/mol，围绕 N(CO)–C2' 键旋转的 ΔG 等于 15.6 ± 0.3 kcal/mol 。首

  DOI：

  10.3390/molecules27020430
• 作为产物：
  描述：

  2,4-二氧代-4-(2-噻吩)丁酸乙酯 在 氯化亚砜 、 sodium hydroxide 作用下， 以 四氯化碳 、 乙醇 、 水 为溶剂， 反应 2.0h， 生成 1-甲基-5-噻吩-2-基-1H-吡唑-3-羰酰氯
  参考文献：
  名称：

  Design and Evaluation of Bispidine-Based SARS-CoV-2 Main Protease Inhibitors

  摘要：

  DOI：

  10.1021/acsmedchemlett.1c00299

文献信息

• [EN] INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] DÉRIVÉS D'INDOLAMIDE ET COMPOSÉS ASSOCIÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DES MALADIES NEURODÉGÉNÉRATIVES
  申请人：UNIV LEUVEN KATH

  公开号：WO2010142801A1

  公开（公告）日：2010-12-16

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  本发明提供了新型化合物，以及这些新型化合物作为药物的使用，特别是用于预防或治疗神经退行性疾病，更具体地是一些神经系统疾病，例如统称为tauopathies的疾病，以及以细胞毒性α-突触核蛋白淀粉样蛋白生成为特征的疾病。本发明还涉及将所述新型化合物用于制造用于治疗此类神经退行性疾病的药物。本发明还涉及包括所述新型化合物的药物组合物，以及制备所述新型化合物的方法。
• INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Griffioen Gerard

  公开号：US20120083475A1

  公开（公告）日：2012-04-05

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  该发明提供了新型化合物，以及这些新型化合物用作药物，特别是用于预防或治疗神经退行性疾病，更具体地说是某些神经系统疾病，例如被统称为tau病理学的疾病，以及由细胞毒性α-突触蛋白淀积所特征的疾病。本发明还涉及使用这些新型化合物制备治疗这种神经退行性疾病的药物。本发明还涉及包括这些新型化合物的制药组合物，以及制备这些新型化合物的方法。
• Synthesis of non-symmetric N-benzylbispidinol amides and study of their inhibitory activity against the main protease of the SARS-CoV-2 virus
  作者：A. I. Dalinger、D. S. Baev、O. I. Yarovaya、V. Yu. Chirkova、E. A. Sharlaeva、S. V. Belenkaya、D. N. Shcherbakov、N. F. Salakhutdinov、S. Z. Vatsadze

  DOI：10.1007/s11172-023-3729-x

  日期：2023.1

  Based on the data obtained by molecular modeling of the non-covalent interaction of non-symmetric N-benzylbispidin-9-ol amides with the active site of the main protease 3CLpro of the SARS-CoV-2 virus, a series of compounds was synthesized, and their inhibitory activity against 3CLpro was studied and compared with that of the known inhibitor ML188 (IC50 = 1.56±0.55 µmol L−1). It was found that only compound 1g containing the 1,4-dihydroindeno[1,2-c]pyrazole fragment showed moderate activity (IC50 = 100±5.7µmol L−1) and was characterized by the highest calculated binding energy among the studied bispidine derivatives according to molecular docking data.

  根据非对称N-苄基双哌啶-9-醇酰胺与SARS-CoV-2病毒主要蛋白酶3CLpro活性位点的非共价相互作用分子建模获得的数据，合成了一系列化合物，并研究了它们对3CLpro的抑制活性，并与已知的抑制剂ML188（IC50 = 1.56±0.55 µmol L-1）进行了比较。结果发现，只有含有1,4-二氢茚并[1,2-c]吡唑片段的化合物1g表现出中等活性（IC50 = 100±5.7µmol L-1），并且根据分子对接数据，在所研究的双哌啶衍生物中具有最高的计算结合能。
• Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases
  申请人：Katholieke Universiteit Leuven, K.U.Leuven R&D

  公开号：US10117850B2

  公开（公告）日：2018-11-06

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  本发明提供了新型化合物和用作药物的新型化合物，尤其是用于预防或治疗神经退行性疾病，更具体地说，用于预防或治疗某些神经系统疾病，如统称为tauopathies的疾病，以及以细胞毒性α-突触核蛋白淀粉样蛋白生成为特征的疾病。本发明还涉及使用所述新型化合物制造治疗此类神经退行性疾病的药物。本发明进一步涉及包括所述新型化合物的药物组合物以及制备所述新型化合物的方法。
• THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：GRIFFIOEN Gerard

  公开号：US20090054410A1

  公开（公告）日：2009-02-26

  This invention provides specifically substituted 1,2,4-thiadiazole derivatives for use in the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides various methods for producing such substituted 1,2,4-thiadiazole derivatives.